IPPI's vincristine
Executive Summary
International Pharmaceutical Products announced the settlement of a patent infringement suit filed by Lilly covering the anticancer drug. "Eli Lilly acknowledged . . . that IPPI's formulation, as presently constituted (without added acid), does not infringe on Lilly's U.S. patent. IPPI . . . has withdrawn their counter-claims," company said. DuPont Critical Care markets IPPI's vincristine product.